Clinical/biomarker data for neoadjuvant atezolizumab in resectable stage IB-IIIB NSCLC: Primary analysis in the LCMC3 study Meeting Abstract
| Authors: | Carbone, D.; Lee, J.; Kris, M.; Wistuba, I.; Kwiatkowski, D.; Owen, D.; Bunn, P.; Johnson, B.; Oezkan, F.; Tang, Y.; Parra, E. R.; Lozanski, G.; Rivard, C.; Schulze, K.; Nicholas, A.; Johnson, A.; Grindheim, J.; Shames, D.; Phan, S.; Toloza, E.; Haura, E.; McNamee, C.; Gainor, J.; Patterson, A.; Waqar, S.; Raz, D.; Reckamp, K.; Finley, D.; Rusch, V.; Chaft, J.; Abel, J. |
| Abstract Title: | Clinical/biomarker data for neoadjuvant atezolizumab in resectable stage IB-IIIB NSCLC: Primary analysis in the LCMC3 study |
| Meeting Title: | 2020 World Conference on Lung Cancer |
| Keywords: | neoadjuvant; atezolizumab; early stage lung cancer |
| Journal Title: | Journal of Thoracic Oncology |
| Volume: | 16 |
| Issue: | 3 Suppl. |
| Meeting Dates: | 2021 Jan 28-31 |
| Meeting Location: | Singapore |
| ISSN: | 1556-0864 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2021-03-01 |
| Start Page: | S115 |
| End Page: | S116 |
| Language: | English |
| ACCESSION: | WOS:000631349600094 |
| PROVIDER: | wos |
| DOI: | 10.1016/j.jtho.2021.01.294 |
| Notes: | Meeting Abstract: OA06.06 -- Due to Covid-19 pandemic, the conference was held virtually -- Source: Wos |
